 |
FSD Pharma
HUGE
|
3.11 K |
- |
5743.5 % |
$ 69.7 M |
Canada |
 |
Happiness Biotech Group Limited
HAPP
|
1.94 K |
- |
1.35 % |
$ 17.8 M |
China |
 |
AgeX Therapeutics
AGE
|
186 |
- |
-10.17 % |
$ 12.2 K |
USA |
 |
Coherus BioSciences
CHRS
|
656 |
$ 1.69 |
2.74 % |
$ 198 M |
USA |
 |
I-Mab
IMAB
|
271 |
- |
- |
$ 866 M |
China |
 |
Celldex Therapeutics
CLDX
|
321 |
$ 31.72 |
2.82 % |
$ 2.11 B |
USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 |
- |
- |
$ 40.3 B |
USA |
 |
AstraZeneca PLC
AZN
|
206 |
- |
- |
$ 96.9 B |
Britain |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K |
$ 53.82 |
4.33 % |
$ 4.84 B |
Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 |
- |
-1.52 % |
$ 24.7 M |
USA |
 |
Compugen Ltd.
CGEN
|
400 |
$ 2.76 |
3.96 % |
$ 258 M |
Israel |
 |
Midatech Pharma plc
MTP
|
245 |
- |
-18.52 % |
$ 27.3 M |
Britain |
 |
Esperion Therapeutics
ESPR
|
99.7 |
$ 3.13 |
0.16 % |
$ 651 M |
USA |
 |
Eton Pharmaceuticals
ETON
|
189 |
$ 31.98 |
2.21 % |
$ 861 M |
USA |
 |
Affimed N.V.
AFMD
|
31.4 |
- |
-34.95 % |
$ 21.5 M |
Germany |
 |
Институт стволовых клеток человека
ISKJ
|
104 |
- |
- |
- |
Russia |
 |
Celyad Oncology SA
CYAD
|
64.4 |
- |
- |
$ 12.5 M |
Belgium |
 |
Berkeley Lights
BLI
|
349 |
- |
-7.31 % |
$ 87 M |
USA |
 |
Generation Bio Co.
GBIO
|
47.6 |
- |
- |
$ 344 M |
USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 |
- |
- |
$ 7.46 M |
Israel |
 |
Grifols, S.A.
GRFS
|
0.000171 |
$ 8.02 |
0.06 % |
$ 5.45 B |
Spain |
 |
Hutchison China MediTech Limited
HCM
|
144 |
$ 11.78 |
0.26 % |
$ 10.1 B |
China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
185 |
- |
-4.36 % |
$ 27 M |
USA |
 |
Heron Therapeutics
HRTX
|
842 |
$ 0.9 |
1.45 % |
$ 150 M |
USA |
 |
ImmuCell Corporation
ICCC
|
232 |
$ 10.62 |
1.1 % |
$ 95.9 M |
USA |
 |
Anika Therapeutics
ANIK
|
235 |
$ 14.67 |
-1.48 % |
$ 210 M |
USA |
 |
Advaxis
ADXS
|
3.28 K |
- |
-9.65 % |
$ 45.9 M |
USA |
 |
Aeterna Zentaris
AEZS
|
115 |
- |
5.93 % |
$ 314 M |
Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 |
- |
- |
$ 26.5 M |
USA |
 |
AIkido Pharma
AIKI
|
17.9 |
- |
1.93 % |
$ 17.4 M |
USA |